The post BTC ETFs Set 53 Billion Dollar Net Inflow Record appeared on BitcoinEthereumNews.com. US spot BTC detailed analysis ETFs have experienced intense outflowsThe post BTC ETFs Set 53 Billion Dollar Net Inflow Record appeared on BitcoinEthereumNews.com. US spot BTC detailed analysis ETFs have experienced intense outflows

BTC ETFs Set 53 Billion Dollar Net Inflow Record

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

US spot BTC detailed analysis ETFs have experienced intense outflows recently, but the overall picture tells a different story. According to Bloomberg ETF analyst Eric Balchunas, cumulative net inflows into BTC ETFs reached 63 billion dollars in October and are currently at around 53 billion dollars. This figure greatly exceeds Bloomberg’s early estimates (5-15 billion dollars). Balchunas shared data compiled by James Seyffart on the X platform, emphasizing that this is a net 53 billion dollar success in two years.

Source: Eric Balchunas

Record-Breaking Facts in BTC ETF Flows

Spot BTC ETFs approved at the beginning of 2024 have become the dominant force in the market. BlackRock’s iShares Bitcoin Trust reached 70 billion dollars in assets in one year, breaking the record for the fastest-growing ETF. BTC reached new highs before the April 2024 halving, ETF accumulation accelerated in 2025, and it exceeded 126 thousand dollars in October. According to current news, even though Google searches for “Will Bitcoin go to zero?” are increasing, institutional buyers (like Morgan Stanley) continue to accumulate BTC.

Bitcoin and crypto more generally underperformed other risk assets in 2025. Source: Wintermute

Critical Support and Resistance Levels for BTC

  • Price: $66,987.22 (+1.22% 24h)
  • RSI: 34.43 (Oversold)
  • Trend: Bearish (Supertrend: Bearish, EMA20: $71,660)
  • Supports: S1 $65,083 (Strong, -2.87%), S2 $62,910 (Strong, -6.11%)
  • Resistances: R1 $68,408 (Strong, +2.10%), R2 $70,606 (Strong, +5.38%)

With the January-February 2026 sell-off, BTC fell back to 60 thousand dollars. The four-year cycle is extending; Bitwise analysts say it has changed due to the influence of institutional capital (Merrill Lynch). In 2025, BTC underperformed risk assets, and retail interest decreased.

BTC Market Cycle and Institutional Impact

Bitcoin mining company Hive increased its hash rate despite a 91 million dollar loss. Quantum security updates like BIP-360 will take 7 years. BTC futures remain dominant.

Frequently Asked Questions About BTC ETF Inflows

  • How much net inflow have BTC ETFs received? 53 billion dollars cumulative.
  • What do the recent outflows mean? Short-term, long-term accumulation is strong.
  • Has the BTC cycle ended? Extended with institutional interest.

Market Analyst: Sarah Chen

Technical analysis and risk management specialist

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/btc-etfs-set-53-billion-dollar-net-inflow-record

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09